Scholarlink

Background <p>This study evaluated whether pancreatic juice carcinoembryonic antigen (PJ-CEA) measurement during serial pancreatic juice aspiration cytologic examination (SPACE) enhanced diagnostic accuracy and was associated with subsequent pancreatic cancer (PC) diagnosis, especially in cytology-negative patients.</p> Methods <p>We retrospectively analyzed 206 patients undergoing both SPACE and PJ-CEA testing. Patients were classified into definitive diagnosis (intraductal papillary mucinous neoplasm [IPMN], non-malignant controls, or PC) and non-definitive diagnosis groups. Because PJ-CEA may be elevated in IPMN regardless of malignant potential, the cutoff for distinguishing PC from non-malignant controls was determined by ROC analysis after excluding IPMN cases from the definitive diagnosis group. Diagnostic performance was compared for SPACE alone, PJ-CEA alone, and their combination. In the non-definitive diagnosis group, cumulative PC incidence was compared between high and low PJ-CEA subgroups using Kaplan–Meier analysis.</p> Results <p>The optimal PJ-CEA cutoff was 7.9&#xa0;ng/mL (AUC 0.924). In the definitive diagnosis group, sensitivity increased from 51.2% with SPACE alone to 86.0% when combined with PJ-CEA (<i>p</i> &lt; 0.001). In the non-definitive diagnosis group, elevated PJ-CEA (≥ 7.9&#xa0;ng/mL) was associated with subsequent PC (HR 11.7, <i>p</i> = 0.025), with a higher cumulative incidence in the high PJ-CEA subgroup (<i>p</i> = 0.019). These findings are based on a limited number of events and should be interpreted as exploratory, requiring external validation.</p> Conclusions <p>After excluding radiologically identifiable IPMN, PJ-CEA measurement during SPACE may improve diagnostic sensitivity for PC and may provide preliminary information for exploratory risk stratification in cytology-negative patients. Further external validation is required before PJ-CEA can be used to guide re-testing and surveillance strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pancreatic juice CEA during SPACE for pancreatic duct stenosis: diagnostic and exploratory risk stratification value

  • 期刊论文

  • 发表日期：

    2026年7月6日

查看全文
  • Tetsuya Okuwaki,
  • Shinichi Takano,
  • Satoshi Kawakami,
  • Natsuhiko Kuratomi,
  • Dai Yoshimura,
  • Koji Yamashita,
  • Makoto Kadokura,
  • Mitsuharu Fukasawa,
  • Hiroko Shindo,
  • Shinya Maekawa,
  • Nobuyuki Enomoto,
  • Atsunori Tsuchiya

摘要

Background

This study evaluated whether pancreatic juice carcinoembryonic antigen (PJ-CEA) measurement during serial pancreatic juice aspiration cytologic examination (SPACE) enhanced diagnostic accuracy and was associated with subsequent pancreatic cancer (PC) diagnosis, especially in cytology-negative patients.

Methods

We retrospectively analyzed 206 patients undergoing both SPACE and PJ-CEA testing. Patients were classified into definitive diagnosis (intraductal papillary mucinous neoplasm [IPMN], non-malignant controls, or PC) and non-definitive diagnosis groups. Because PJ-CEA may be elevated in IPMN regardless of malignant potential, the cutoff for distinguishing PC from non-malignant controls was determined by ROC analysis after excluding IPMN cases from the definitive diagnosis group. Diagnostic performance was compared for SPACE alone, PJ-CEA alone, and their combination. In the non-definitive diagnosis group, cumulative PC incidence was compared between high and low PJ-CEA subgroups using Kaplan–Meier analysis.

Results

The optimal PJ-CEA cutoff was 7.9 ng/mL (AUC 0.924). In the definitive diagnosis group, sensitivity increased from 51.2% with SPACE alone to 86.0% when combined with PJ-CEA (p < 0.001). In the non-definitive diagnosis group, elevated PJ-CEA (≥ 7.9 ng/mL) was associated with subsequent PC (HR 11.7, p = 0.025), with a higher cumulative incidence in the high PJ-CEA subgroup (p = 0.019). These findings are based on a limited number of events and should be interpreted as exploratory, requiring external validation.

Conclusions

After excluding radiologically identifiable IPMN, PJ-CEA measurement during SPACE may improve diagnostic sensitivity for PC and may provide preliminary information for exploratory risk stratification in cytology-negative patients. Further external validation is required before PJ-CEA can be used to guide re-testing and surveillance strategies.